Precision BioSciences has agreed to a second licensing deal for its ‘off-the-shelf’ CAR-T therapy azer-cel, as it switches focus to developing in vivo applications of its
2seventy bio is slashing 40% of its workforce to conserve cash as it tries to build momentum for its FDA-approved CAR-T therapy, while chief executive Nick Leschly is also
With the continuing evolution of the CAR-T landscape, Research Partnership speaks to payers across Europe to investigate the market access and commercialisation potential for manufacturers
In another look back to ASCO 2023, pharmaphorum editor-in-chief Jonah Comstock spoke with Janssen's Martin Vogel and Edmond Chan, EMEA leads for oncology and haematology, respectively.
Shares in 2seventy bio were on the slide this morning after the US biotech said Seattle Children’s Therapeutics had paused a clinical trial of its T-cell therapy for acute
South Korea’s Hyundai Bioscience is preparing to start clinical trials of what it hopes could become the first antiviral treatment for dengue fever, a mosquito-borne viral
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.